Featured Research

from universities, journals, and other organizations

Residual damage after heart attack no longer inevitable

Date:
October 7, 2011
Source:
Medical University of Vienna
Summary:
A new treatment could revolutionize the treatment of patients after a heart attack. Medical researchers have developed a protein solution which can be used to reduce the scarring of tissue caused by inflammation after a heart attack.

Residual damage after heart attack no longer inevitable – MedUni Vienna unveils revolutionary approach to treatment
Credit: Image courtesy of Medical University of Vienna

A new treatment could revolutionize the treatment of patients after a heart attack. Hendrik Jan Ankersmit from the Medical University of Vienna has developed a protein solution which can be used to reduce the scarring of tissue caused by inflammation after a heart attack.

Related Articles


In 2009, 16,000 people were admitted to Austrian hospitals with an acute myocardial infarction, with 3,000 of them dying (source: Statistik Austria). Comparable figures from the European Union reveal 2.2 million deaths caused by ischaemic heart disease (source: WHO). Following the usually critical first phase of a heart attack, intensive rehabilitation is carried out and there is a risk of heart failure.

The results of the research carried out by Hendrik Jan Ankersmit, head of the CD Laboratory for Heart and Thorax Diagnosis and Regeneration at the MedUni Vienna, show that this need no longer be the case. Ankersmit has used white blood cells to create a protein solution (APOSEC™) that can be used as a drug during the acute therapy phase following a heart attack. In laboratory tests, the solution was administered as an intravenous infusion 40 minutes after an experimental infarction. As a result, there was virtually no scarring of the heart muscle.

APOSEC™ works by inhibiting the cardiac tissue's inflammatory response following a heart attack. Tests on human cardiac muscle cells -- with highly promising results -- have already been carried out in vitro. Researchers at the MedUni Vienna are hoping to start a series of clinical studies on humans in the near future.

Like blood in a blood bank -- available at all times APOSEC™ contains soluble proteins that are excreted by white blood cells. Harvesting white blood cells for use as 'bio-reactors' is as simple as taking blood. "With protein concentrates, there is little or no defence reaction from the body's immune system. APOSEC™ can therefore be obtained even from unrelated donors," says Ankersmit.

An even greater potential advantage over the conventional stem-cell-based treatment of myocardial infarctions is that the APOSEC™ protein solution can be produced in advance and stored for ready access, just like blood in a blood bank. In the event of an acute infarction, the patient can be treated immediately.


Story Source:

The above story is based on materials provided by Medical University of Vienna. Note: Materials may be edited for content and length.


Journal Reference:

  1. Lichtenauer M, Mildner M, Hoetzenecker K, Zimmermann M, Podesser BK, Sipos W, Berényi E, Dworschak M, Tschachler E, Gyöngyösi M, Ankersmit HJ. Secretome of apoptotic peripheral blood cells (APOSEC) confers cytoprotection to cardiomyocytes and inhibits tissue remodelling after acute myocardial infarction: a preclinical study. Basic Res Cardiol, 2011, Sep. 28

Cite This Page:

Medical University of Vienna. "Residual damage after heart attack no longer inevitable." ScienceDaily. ScienceDaily, 7 October 2011. <www.sciencedaily.com/releases/2011/10/111006084034.htm>.
Medical University of Vienna. (2011, October 7). Residual damage after heart attack no longer inevitable. ScienceDaily. Retrieved November 27, 2014 from www.sciencedaily.com/releases/2011/10/111006084034.htm
Medical University of Vienna. "Residual damage after heart attack no longer inevitable." ScienceDaily. www.sciencedaily.com/releases/2011/10/111006084034.htm (accessed November 27, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, November 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins